While biofilms are pervasive and are usually the most prevalent mode of bacterial growth, this has lead studies to develop treatments that combat its growth and formation. So far, the developed treatments, novel products, and other processes on wound care have generated a US$4.5 billion profit annually in the global market.

The National Institute of Health (NIH) in the US has accorded an estimate of 80% of biofilms as the cause of most, if not all, bacterial infections. This has cost a lot of damages in health care, food and other industries, hospitals, and even the government. Nonetheless, medications, prescriptions, and other products are developed to combat biofilm formation and prevent further microbial, bacterial, and even chronic and aggressive viral infections in the body.


DispersinB – this is an enzyme that naturally occurs in the body and can combat biofilm formation, disperses it, and even inhibits bacterial adhesion. This is commonly used as a treatment for wounds and otic infections that can be chronic when infected by bacterial biofilms, which are persistent in nature. The target in using this product is to stop the formation of biofilms, destroy the bacteria that infect the wound, and cure the wound towards its healing stage.

Strix Wound Care – while this is in development, this product is expected to cure inflammatory skin disorders like atopic and seborrheic dermatitis, athlete’s foot, and other fungal infections. This will come in shampoo and skincare formulations and will be released to the market once development of the product is complete.